Healthcare use and costs of MCAD deficiency in Australia: screening versus no screening
Haas M., Chaplin M., Joy P., Wiley V., Black C., and Wilcken B. Healthcare use and costs of MCAD deficiency in Australia: screening versus no screening. J Pediatr 151 (2007) 121-126
Cost-effectiveness of neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: the homogeneous population of the Netherlands
van der Hilst C.S., Derks T.G.J., Reijngoud D.-J., Smit P.A., and Ten Vergert E.M. Cost-effectiveness of neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: the homogeneous population of the Netherlands. J Pediatr 151 (2007) 115-120
Newborn screening with tandem mass spectrometry:examining its cost-effectiveness in the Wisconsin newborn screening panel
Insinga R.P., Laessig R.H., and Hoffman G.L. Newborn screening with tandem mass spectrometry:examining its cost-effectiveness in the Wisconsin newborn screening panel. J.Pediatr 141 (2002) 524-531
Cost-benefit analysis of universal tandem mass spectrometry for newborn screening
Schoen E.J., Baker J.C., Colby C.J., and To T.T. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 110 (2002) 781-786